Deals
Cleared $22B: Q1 2026 Obesity Deals Top 2025's Full-Year Total
Biopharma committed $22 billion to obesity and diabetes licensing deals in Q1 2026, clearing last year's full-year total of $20.3 billion with three…
Tag
AstraZeneca
5 stories
FDA
Beats Venetoclax: Lilly's Jaypirca Posts 4th Phase 3 Win in CLL
Jaypirca chalked up its fourth positive phase 3 readout in chronic lymphocytic leukemia on Monday, and this one rewrites the treatment calculus: it's the…
Deals
Regeneron Paid $40M to Enter Radiopharma; Telix Scores Up to $4.3B
Regeneron put $40 million on the table Sunday to partner with Telix Pharmaceuticals, the Australian biotech with one of the more active radiopharmaceutical…
Deals
Syneron Bio Pulls $150M Series B Four Months After $100M Round
Syneron Bio raises $150M Series B, bringing total funding to $250M in four months, backed by AstraZeneca and Abu Dhabi sovereign wealth.
Deals
Lilly Pays $115M Upfront in Insilico AI Deal Worth Up to $2.75B
Eli Lilly paid $115M upfront for an AI collaboration with Insilico Medicine worth up to $2.75B, with milestone math that heavily favors Lilly.
